Iatrogenic Rheumatic Syndromes in the Elderly

Rheumatic Disease Clinics of North America

Volumn 33, Issue 1, 2007, Pages 123-134

  Quiceno, G Andres ^a   Cush, John J ^a  

^a PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALCOHOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CERIVASTATIN; CHLORPROMAZINE; CYTOTOXIC AGENT; DIURETIC AGENT; ETANERCEPT; FLUINDOSTATIN; HYDRALAZINE; INFLIXIMAB; ISONIAZID; LITHIUM; METHYLDOPA; MEVINOLIN; MINOCYCLINE; PENICILLAMINE; PHENYTOIN; PRAVASTATIN; PROCAINAMIDE; PROPYLTHIOURACIL; QUINIDINE; ROSUVASTATIN; SALAZOSULFAPYRIDINE; SIMVASTATIN; THIAMAZOLE; UNINDEXED DRUG; WARFARIN;

CLINICAL FEATURE; DISEASE ASSOCIATION; GOUT; HUMAN; IATROGENIC DISEASE; MYOPATHY; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

AGED; ARTHRALGIA; COLCHICINE; CONNECTIVE TISSUE DISEASES; CREATINE KINASE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IATROGENIC DISEASE; MUSCULAR DISEASES; RHEUMATIC DISEASES; SYNDROME;

EID: 33947120201     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.12.010     Document Type: Review

References (40)

1. Thompson P.D., Clarkson P., and Kara R.H. Statin associated myopathy. JAMA 289 13 (2003) 1681-1690
2. Jamal S.M., Eisenberg M.J., and Chrsitopoulos S. Rhabdomyolysis associated with hydroxymethyl-glutaryl-coenzyme A reductase inhibitors. Am Heart J 147 6 (2004) 956-965
3. Ballantyne C.M., Corsine A., Davidson M.H., et al. Risk of myopathy with statin therapy in high-risk patients. Arch Intern Med 163 (2003) 553-564
4. Daugird A.J., and Crowell K. Do statins cause myopathy?. J Fam Pract 52 12 (2003) 973-976
5. Pasternak R.C., Smith S.C., Bairey-Merz C.N., et al. ACC/AHA/NIHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 (2000) 567-572
6. Mantel-Teeuwise A.K., et al. Myopathy due to statin/fibrate use in the Netherlands. Ann Pharmacother 36 12 (2002) 1957-1960
7. Gaist D., et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12 5 (2001) 565-569
8. Prieto J.C. Safety profile of statins. Rev Med Chil 129 11 (2001) 1237-1240
9. Evans M., and Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all the statins the same?. Drug Saf 25 9 (2002) 649-663
10. Borrego F.J., et al. Rhabdomyolisis and acute renal failure secondary to statins. Nefrologia 21 3 (2001) 309-313
11. Reineveld J.C., et al. Differen effects of 3-hydroxy-3methylgluaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res 39 6 (1996) 1028-1035
12. Williams D., and Feeley J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41 5 (2002) 343-370
13. Slater E.E., et al. Mechanism of action and biological profile of HMG CoA reductase inhibitors. Drugs 36 Suppl 3 (1998) 72-82
14. Corsini A., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmachol Ther 84 (1999) 413-428
15. Paoiletti R., et al. Pharmacological interactions of statins. Atheroscler Suppl 3 1 (2002) 35-40
16. Matzno S., Tazuya-Murayama K., Tanaka H., et al. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J Pharm Pharmacol 55 6 (2003) 795-802
17. Phillips P.S., Hass R.H., Bannykhs S., et al. Statin-associated myopathy with normal creatinine kinase levels. Ann Intern Med 137 7 (2002) 581-585
18. Farne J.A. Statin and myotoxicity. Curr Atheroscler Rep 5 2 (2003) 96-100
19. Carvalho A.A., et al. Statin and fibrate associated myopathy: study of eight patients. Arq Neuropsiquiatr 62 2A (2004) 257-261
20. Calkins E., and Vladutiu A. Drug induced lupus. Musculoskeletal disorders. In: Duthie E.H., and Katz P. (Eds). Practice of geriatrics. 3rd ed. (1998), WB Saunders, Philadelphia 430
21. Olsen N.J. Drug-induced autoimmunity. Baillieres Best Pract Res Clin Rheumatol 18 5 (2004) 677-688
22. Blazes D.L., and Martin G.J. Drug-induced lupus erythematosus secondary to nafcillin: the first reported case. Rheumatol Int 24 4 (2004) 242-243
23. Buyon J.P. Drug-related Lupus. Primer on the rheumatic diseases. 12th ed. (2001), The Arthritis Foundation, Atlanta (GA) p. 345
24. Ferri F.F. Systemic Lupus Erythematosus. In: Ferri F.F. (Ed). Practical guide to the care of the medical patient. 6th ed. (2004), Mosby, Inc., St. Louis 810-811
25. Cohen M.G., and Prowse M.V. Drug-induced rheumatic syndromes. Diagnosis, clinical features and management. Med Toxicol Adverse Drug Exp 4 3 (1989) 199-218
26. Asherson R.A., Zulman J., et al. Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies. Ann Rheum Dis 48 3 (1989) 232-235
27. Turgeon P.W., and Slamovits T.L. Scleritis as the presenting manifestation of procainamide-induced lupus. Ophthalmology 96 1 (1989) 68-71
28. Sherertz E.F. Lichen planus following procainamide-induced lupus erythematosus. Cutis 42 1 (1988) 51-53
29. Maxwell D., and Silver R. Laryngeal manifestations of drug induced lupus. J Rheumatol 14 2 (1987) 375-377
30. Wing S.S., and Fantus I.G. Adverse immunological effects of antithyroid drugs. CMAJ 136 2 (1987) 12-17
31. Cush J.J., and Kavanaugh A.F. Drug-induced lupus. In: Cush J.J., and Kavanaugh A.F. (Eds). Rheumatology diagnosis and therapeutics (1999), Williams & Wilkins, Baltimore (MD) 193-197
32. Epstein A., and Barland P. The diagnostic value of antihistone antibodies in drug-induced lupus erythematosus. Arthritis Rheum 28 2 (1985) 158-162
33. Bray V.J., West S.G., Schultz K.T., et al. Antihistone antibody profile in sufasalazine induced lupus. J Rheumatol 21 11 (1994) 2157-2158
34. Rubin R.L. Etiology and mechanism of drug-induced lupus. Curr Opin Rheumatol 11 5 (1999) 357-363
35. Kim K.Y., Ralph Schumacher H., Hunsche E., et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 25 (2003) 1593-1617
36. Rott K.T., and Agudelo C.A. Gout. JAMA 289 (2003) 2857-2860
37. Cush J.J., Kavanaugh A., and Stein M.F. Gout. In: Cush J.J., Kavanaugh A., and Stein M.F. (Eds). Rheumatology: diagnosis and therapeutics (2005), Lippincott Williams & Wilkins, Philadelphia 187-195
38. Boomershine K.H. Colchicine-induced rhabdomyolysis. Ann Pharmacother 36 5 (2002) 824-826
39. ten Holder S.M., Joy M.S., and Falk R.J. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 36 1 (2002) 130-147
40. Doyle M.K., and Cuellar M.L. Drug-induced vasculitis. Expert Opin Drug Saf 2 4 (2003) 401-409